# L_2005224EN.01000701.xml

| 30.8.2005 | EN | Official Journal of the European Union | L 224/7 |
| --- | --- | --- | --- |

30.8.2005

EN

Official Journal of the European Union

L 224/7

---

COMMISSION DECISION

of 23 August 2005

on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2005 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council

(notified under document number C(2005) 333)

(Only the Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Slovenian, Spanish and Swedish texts are authentic)

(Text with EEA relevance)

(2005/626/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 2037/2000 of the European Parliament and of the Council of 29 June 2000 on substances that deplete the ozone layer (1), and in particular Article 3(1) thereof,

Whereas:

| (1) | The Community has already phased out the production and consumption of chlorofluorocarbons, other fully halogenated chlorofluorocarbons, halons, carbon tetrachloride,1,1,1-trichloroethane, hydrobromofluorocarbon and bromo-chloromethane. |
| --- | --- |

(1)

The Community has already phased out the production and consumption of chlorofluorocarbons, other fully halogenated chlorofluorocarbons, halons, carbon tetrachloride,1,1,1-trichloroethane, hydrobromofluorocarbon and bromo-chloromethane.

| (2) | Each year the Commission is required to determine essential uses for these controlled substances, the quantities that may be used and the companies that may use them. |
| --- | --- |

(2)

Each year the Commission is required to determine essential uses for these controlled substances, the quantities that may be used and the companies that may use them.

| (3) | Decision IV/25 of the Parties to the Montreal Protocol on Substances that Deplete the Ozone Layer, hereinafter ‘the Montreal Protocol’, sets out the criteria used by the Commission for determining any essential uses and authorises the production and consumption necessary to satisfy essential uses of controlled substances in each Party. |
| --- | --- |

(3)

Decision IV/25 of the Parties to the Montreal Protocol on Substances that Deplete the Ozone Layer, hereinafter ‘the Montreal Protocol’, sets out the criteria used by the Commission for determining any essential uses and authorises the production and consumption necessary to satisfy essential uses of controlled substances in each Party.

| (4) | Decision XV/8 of the Parties to the Montreal Protocol authorises the production and consumption necessary to satisfy essential uses of controlled substances listed in Annexes A, B and C (Group II and III substances) of the Montreal Protocol for laboratory and analytical uses as listed in Annex IV to the report of the Seventh Meeting of the Parties, subject to the conditions set out in Annex II to the report of the Sixth Meeting of the Parties, Decision VII/11 and Decision XI/15 of the Parties to the Montreal Protocol. |
| --- | --- |

(4)

Decision XV/8 of the Parties to the Montreal Protocol authorises the production and consumption necessary to satisfy essential uses of controlled substances listed in Annexes A, B and C (Group II and III substances) of the Montreal Protocol for laboratory and analytical uses as listed in Annex IV to the report of the Seventh Meeting of the Parties, subject to the conditions set out in Annex II to the report of the Sixth Meeting of the Parties, Decision VII/11 and Decision XI/15 of the Parties to the Montreal Protocol.

| (5) | Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free Metered-Dose Inhalers (MDIs), Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Latvia, Lithuania, Luxembourg, Poland, Norway, Portugal, The Netherlands, Slovak Republic, Slovenia, Spain, Sweden and the United Kingdom have notified the United Nations Environment Programme (2) that chlorofluorocarbons (CFCs) are no longer essential for the manufacture of CFC-MDIs that contain active ingredients belonging to the therapeutic categories of ‘short-acting beta agonist bronchiodilators’, ‘inhaled steroids’ and ‘anticholinergic bronchiodilators’. Article 4(4)(i)(b) of Regulation (EC) No 2037/2000 prevents CFCs from being used and placed on the market unless they are considered essential under the conditions described in Article 3(1) of that Regulation. These non-essentiality determinations have reduced the demand for CFCs in the Community. In addition, Article 4(6) of Regulation (EC) No 2037/2000 prevents CFC-MDI products being imported and placed on the market unless the CFCs in these products are considered essential under the conditions described in Article 3(1). |
| --- | --- |

(5)

Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free Metered-Dose Inhalers (MDIs), Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Latvia, Lithuania, Luxembourg, Poland, Norway, Portugal, The Netherlands, Slovak Republic, Slovenia, Spain, Sweden and the United Kingdom have notified the United Nations Environment Programme (2) that chlorofluorocarbons (CFCs) are no longer essential for the manufacture of CFC-MDIs that contain active ingredients belonging to the therapeutic categories of ‘short-acting beta agonist bronchiodilators’, ‘inhaled steroids’ and ‘anticholinergic bronchiodilators’. Article 4(4)(i)(b) of Regulation (EC) No 2037/2000 prevents CFCs from being used and placed on the market unless they are considered essential under the conditions described in Article 3(1) of that Regulation. These non-essentiality determinations have reduced the demand for CFCs in the Community. In addition, Article 4(6) of Regulation (EC) No 2037/2000 prevents CFC-MDI products being imported and placed on the market unless the CFCs in these products are considered essential under the conditions described in Article 3(1).

| (6) | The Commission has published a Notice (3) on the 22 July 2004 to those companies in the Community of 25 Member States that request consideration by the Commission for the use of controlled substances for essential uses in the Community in 2005 and has received declarations on intended essential uses of controlled substances in 2005. |
| --- | --- |

(6)

The Commission has published a Notice (3) on the 22 July 2004 to those companies in the Community of 25 Member States that request consideration by the Commission for the use of controlled substances for essential uses in the Community in 2005 and has received declarations on intended essential uses of controlled substances in 2005.

| (7) | For the purpose of ensuring that interested companies and operators may continue to benefit in due time from the licensing system, it is appropriate that the present decision shall apply from 1 January 2005. |
| --- | --- |

(7)

For the purpose of ensuring that interested companies and operators may continue to benefit in due time from the licensing system, it is appropriate that the present decision shall apply from 1 January 2005.

| (8) | The measures provided for in this Decision are in accordance with the opinion of the Management Committee established by Article 18(1) of Regulation (EC) No 2037/2000, |
| --- | --- |

(8)

The measures provided for in this Decision are in accordance with the opinion of the Management Committee established by Article 18(1) of Regulation (EC) No 2037/2000,

HAS ADOPTED THIS DECISION:

Article 1

1.   The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) subject to Regulation (EC) No 2037/2000 which may be used for essential medical uses in the Community in 2005 shall be 1 029 770,00 ODP (4) kilograms.

2.   The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) and Group II (other fully halogenated chlorofluorocarbons) subject to Regulation (EC) No 2037/2000 which may be used for essential laboratory uses in the Community in 2005 shall be 63 081,71 ODP kilograms.

3.   The quantity of controlled substances of Group III (halons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory use in the Community in 2005 shall be 70,705 ODP kilograms.

4.   The quantity of controlled substances of Group IV (carbon tetrachloride) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2005 shall be 145 240,293 ODP kilograms.

5.   The quantity of controlled substances of Group V (1,1,1-trichloroethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the European Union in 2005 shall be 815,30 ODP kilograms.

6.   The quantity of controlled substances of Group VII (hydrobromofluorocarbons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2005 shall be 3,04 ODP kilograms.

7.   The quantity of controlled substances of group IX (bromochloromethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2005 shall be 12,048 ODP kilograms.

Article 2

The chlorofluorocarbon metered-dose inhalers (CFC-MDIs) listed in Annex I shall not be placed on markets that have determined CFCs for these products to be non-essential.

Article 3

During the period 1 January to 31 December 2005 the following rules shall apply:

| 1. | The allocation of essential medical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 shall be to the companies indicated in Annex II. |
| --- | --- |

1.

The allocation of essential medical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 shall be to the companies indicated in Annex II.

| 2. | The allocation of essential laboratory use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 and other fully halogenated chlorofluorocarbons shall be to the companies indicated in Annex III. |
| --- | --- |

2.

The allocation of essential laboratory use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 and other fully halogenated chlorofluorocarbons shall be to the companies indicated in Annex III.

| 3. | The allocation of essential laboratory use quotas for halons shall be to the companies indicated in Annex IV. |
| --- | --- |

3.

The allocation of essential laboratory use quotas for halons shall be to the companies indicated in Annex IV.

| 4. | The allocation of essential laboratory use quotas for carbon tetrachloride shall be to the companies indicated in Annex V. |
| --- | --- |

4.

The allocation of essential laboratory use quotas for carbon tetrachloride shall be to the companies indicated in Annex V.

| 5. | The allocation of essential laboratory use quotas for 1,1,1-trichloroethane shall be to the companies indicated in Annex VI. |
| --- | --- |

5.

The allocation of essential laboratory use quotas for 1,1,1-trichloroethane shall be to the companies indicated in Annex VI.

| 6. | The allocation of essential laboratory use quotas for hydrobromofluorocarbons shall be to the companies indicated in Annex VII. |
| --- | --- |

6.

The allocation of essential laboratory use quotas for hydrobromofluorocarbons shall be to the companies indicated in Annex VII.

| 7. | The allocation of essential laboratory use quotas for bromochloromethane shall be to the companies indicated in Annex VIII. |
| --- | --- |

7.

The allocation of essential laboratory use quotas for bromochloromethane shall be to the companies indicated in Annex VIII.

| 8. | The essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, other fully halogenated chlorofluorocarbons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbons and bromochloromethane shall be as set out in Annex IX. |
| --- | --- |

8.

The essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, other fully halogenated chlorofluorocarbons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbons and bromochloromethane shall be as set out in Annex IX.

Article 4

This Decision is addressed to the following undertakings:

| | 3M Health Care Ltd |
| --- | --- |
| 3M House Morley Street |
| Loughborough |
| Leicestershire LE11 1EP |
| United Kingdom |

3M Health Care Ltd

3M House Morley Street

Loughborough

Leicestershire LE11 1EP

United Kingdom

| | Aventis |
| --- | --- |
| London Road, Holmes Chapel |
| Cheshire CW4 8BE |
| United Kingdom |

Aventis

London Road, Holmes Chapel

Cheshire CW4 8BE

United Kingdom

| | Bespak PLC |
| --- | --- |
| North Lynn Industrial Estate |
| King's Lynn |
| PE30 2JJ — Norfolk |
| United Kingdom |

Bespak PLC

North Lynn Industrial Estate

King's Lynn

PE30 2JJ — Norfolk

United Kingdom

| | Boehringer Ingelheim GmbH |
| --- | --- |
| Binger Straße 173 |
| D-55216 Ingelheim am Rhein |

Boehringer Ingelheim GmbH

Binger Straße 173

D-55216 Ingelheim am Rhein

| | Chiesi Farmaceutici SpA |
| --- | --- |
| Via Palermo 26/A |
| I-43100 Parma |

Chiesi Farmaceutici SpA

Via Palermo 26/A

I-43100 Parma

| | GlaxoSmithKline |
| --- | --- |
| Speke Boulevard |
| Speke |
| L24 9JD — Liverpool |
| United Kingdom |

GlaxoSmithKline

Speke Boulevard

Speke

L24 9JD — Liverpool

United Kingdom

| | IG Sprühtechnik GmbH |
| --- | --- |
| Im Hemmet 1 |
| D-79664 Wehr |

IG Sprühtechnik GmbH

Im Hemmet 1

D-79664 Wehr

| | Inyx Pharmaceuticals Ltd |
| --- | --- |
| Astmoor Industrial Estate |
| 9 Arkwright Road RUNCORN |
| Cheshire WA7 1NU |
| United Kingdom |

Inyx Pharmaceuticals Ltd

Astmoor Industrial Estate

9 Arkwright Road RUNCORN

Cheshire WA7 1NU

United Kingdom

| | GlaxoSmithKline Pharmaceuticals SA |
| --- | --- |
| Siedziba w Poznaniu |
| ul. Grunwaldzka 189 |
| 60-322 Poznań |
| Poland |

GlaxoSmithKline Pharmaceuticals SA

Siedziba w Poznaniu

ul. Grunwaldzka 189

60-322 Poznań

Poland

| | IVAX Ltd |
| --- | --- |
| Unit 301 Industrial Park |
| Waterford |
| Ireland |

IVAX Ltd

Unit 301 Industrial Park

Waterford

Ireland

| | Laboratorio Aldo Union SA |
| --- | --- |
| Baronesa de Maldá, 73 |
| Espluges de Llobregat |
| E-08950 Barcelona |

Laboratorio Aldo Union SA

Baronesa de Maldá, 73

Espluges de Llobregat

E-08950 Barcelona

| | SICOR S.p.A |
| --- | --- |
| Via Terrazzano 77 |
| I-20017 Rho (MI) |

SICOR S.p.A

Via Terrazzano 77

I-20017 Rho (MI)

| | Valeas SpA Pharmaceuticals |
| --- | --- |
| Via Vallisneri, 10 |
| I-20133 Milano |

Valeas SpA Pharmaceuticals

Via Vallisneri, 10

I-20133 Milano

| | Valois SA |
| --- | --- |
| 50, avenue de l'Europe |
| F-78160 Marly Le Roi |

Valois SA

50, avenue de l'Europe

F-78160 Marly Le Roi

| | Valvole Aerosol Research Italiana (VARI) |
| --- | --- |
| Spa — LINDAL Group Italia |
| Via del Pino, 10 |
| Olginate (LC) |
| I-23854 |

Valvole Aerosol Research Italiana (VARI)

Spa — LINDAL Group Italia

Via del Pino, 10

Olginate (LC)

I-23854

| | Acros Organics bvba |
| --- | --- |
| Janssen Pharmaceuticalaan 3a |
| B-2440 Geel |

Acros Organics bvba

Janssen Pharmaceuticalaan 3a

B-2440 Geel

| | Agfa-Gevaert NV |
| --- | --- |
| Septestraat 27 |
| B-2640 Mortsel |

Agfa-Gevaert NV

Septestraat 27

B-2640 Mortsel

| | Bie & Berntsen |
| --- | --- |
| Sandbækvej 7 |
| DK-2610 Rødovre |

Bie & Berntsen

Sandbækvej 7

DK-2610 Rødovre

| | Biosolove BV |
| --- | --- |
| Waalreseweg 17 |
| 5554 HA Valkenswaard |
| Nederland |

Biosolove BV

Waalreseweg 17

5554 HA Valkenswaard

Nederland

| | Carl Roth GmbH |
| --- | --- |
| Schoemperlenstraße 3—5 |
| D-76185 Karlsruhe |

Carl Roth GmbH

Schoemperlenstraße 3—5

D-76185 Karlsruhe

| | Elcom Group |
| --- | --- |
| Okružní 988 |
| CZ-735 14 Orlová-Lutyně |

Elcom Group

Okružní 988

CZ-735 14 Orlová-Lutyně

| | Health Protection Inspectorate-Laboratories |
| --- | --- |
| Paldiski mnt 81 |
| EE-10617 Tallinn |

Health Protection Inspectorate-Laboratories

Paldiski mnt 81

EE-10617 Tallinn

| | Honeywell Specialty Chemicals |
| --- | --- |
| Wunstorfer Straße 40 |
| Postfach 100262 |
| D-30918 Seelze |

Honeywell Specialty Chemicals

Wunstorfer Straße 40

Postfach 100262

D-30918 Seelze

| | Ineos Fluor Ltd |
| --- | --- |
| PO Box 13, The Heath |
| Runcorn Cheshire WA7 4QF |
| United Kingdom |

Ineos Fluor Ltd

PO Box 13, The Heath

Runcorn Cheshire WA7 4QF

United Kingdom

| | Institut scientifique de service public (ISSeP) |
| --- | --- |
| Rue du Chéra, 200 |
| B-4000 Liège |

Institut scientifique de service public (ISSeP)

Rue du Chéra, 200

B-4000 Liège

| | Katholieke Universiteit Leuven |
| --- | --- |
| Krakenstraat 3 |
| B-3000 Leuven |

Katholieke Universiteit Leuven

Krakenstraat 3

B-3000 Leuven

| | LGC Promochem GmbH |
| --- | --- |
| Mercatorstraße 51 |
| D-46485 Wesel |

LGC Promochem GmbH

Mercatorstraße 51

D-46485 Wesel

| | Mallinckrodt Baker BV |
| --- | --- |
| Teugseweg 20 |
| 7418 AM Deventer |
| Nederland |

Mallinckrodt Baker BV

Teugseweg 20

7418 AM Deventer

Nederland

| | Merck KGaA |
| --- | --- |
| Frankfurter Straße 250 |
| D-64293 Darmstadt |

Merck KGaA

Frankfurter Straße 250

D-64293 Darmstadt

| | Mikro+Polo d.o.o. |
| --- | --- |
| Zagrebška cesta 22 |
| SI-2000 Maribor |

Mikro+Polo d.o.o.

Zagrebška cesta 22

SI-2000 Maribor

| | Ministry of Defense |
| --- | --- |
| Directorate Material RNLNavy |
| PO Box 2070 |
| 2500 ES The Hague |
| Nederland |

Ministry of Defense

Directorate Material RNLNavy

PO Box 2070

2500 ES The Hague

Nederland

| | Panreac Quimica SA |
| --- | --- |
| Riera de Sant Cugat, 1 |
| E-08110 Montcada I Reixac (Barcelona) |

Panreac Quimica SA

Riera de Sant Cugat, 1

E-08110 Montcada I Reixac (Barcelona)

| | Rohs Chemie GmbH |
| --- | --- |
| Berliner Str. 54 |
| D-53819 Neunkirchen-Seelscheid |

Rohs Chemie GmbH

Berliner Str. 54

D-53819 Neunkirchen-Seelscheid

| | Sanolabor d.d. |
| --- | --- |
| Leskovškova 4 |
| SI-1000 Ljubljana |

Sanolabor d.d.

Leskovškova 4

SI-1000 Ljubljana

| | SDS Solvants, Documentation, Synthèses SA |
| --- | --- |
| Z.I. de Valdonne, BP 4 |
| F-13124 Peypin |

SDS Solvants, Documentation, Synthèses SA

Z.I. de Valdonne, BP 4

F-13124 Peypin

| | Sigma Aldrich Chemie GmbH |
| --- | --- |
| Riedstraße 2 |
| D-89555 Steinheim |

Sigma Aldrich Chemie GmbH

Riedstraße 2

D-89555 Steinheim

| | Sigma Aldrich Chimie SARL |
| --- | --- |
| 80, rue de Luzais |
| L'Isle-d'Abeau Chesne |
| F-38297 Saint-Quentin-Fallavier |

Sigma Aldrich Chimie SARL

80, rue de Luzais

L'Isle-d'Abeau Chesne

F-38297 Saint-Quentin-Fallavier

| | Sigma Aldrich Company Ltd |
| --- | --- |
| The Old Brickyard |
| New Road Gillingham SP8 4XT |
| United Kingdom |

Sigma Aldrich Company Ltd

The Old Brickyard

New Road Gillingham SP8 4XT

United Kingdom

| | Sigma Aldrich Laborchemikalien |
| --- | --- |
| Wunstorfer Straße 40, Postfach 100262 |
| D-30918 Seelze |

Sigma Aldrich Laborchemikalien

Wunstorfer Straße 40, Postfach 100262

D-30918 Seelze

| | VWR I.S.A.S. |
| --- | --- |
| 201 rue Carnot |
| F-94126 Fontenay-sous-Bois |

VWR I.S.A.S.

201 rue Carnot

F-94126 Fontenay-sous-Bois

| | YA-Kemia Oy — Sigma-Aldrich Finland |
| --- | --- |
| Teerisuonkuja 4 |
| FI-00700 Helsinki |

YA-Kemia Oy — Sigma-Aldrich Finland

Teerisuonkuja 4

FI-00700 Helsinki

Article 5

This Decision shall apply from 1 January 2005 and shall expire on 31 December 2005.

Done at Brussels, 23 August 2005.

For the Commission

Stavros DIMAS

Member of the Commission

---

(1)  
  OJ L 244, 29.9.2000, p. 1. Regulation as last amended by Commission Regulation (EC) No 2077/2004 (OJ L 359, 4.12.2004, p. 28).

1

(2)  www.unep.org/ozone/dec12-2-3.shtml

2

(3)  
  OJ C 187, 22.7.2004, p. 24.

3

(4)  Ozone-depleting Potential.

4

---

ANNEX I

Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following active ingredients:

| Country | Salbutamol | Terbutaline | Fenoterol | Orciprenaline | Reproterol | Carbuterol | Hexoprenaline | Pirbuterol | Clenbuterol | Bitolterol | Procaterol | Beclamethasone | Dexamethasone | Flunisolide | Fluticasone | Budesonide | Triamcinolone | Ipratropium bromide | Oxitropium bromide |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Austria | | | | | | | | | | | | | | | | | | | |
| Belgium | | | | | | | | | | | | | | | | | | | |
| Cyprus | | | | | | | | | | | | | | | | | | | |
| Czech Republic | | | | | | | | | | | | | | | | | | | |
| Denmark | | | | | | | | | | | | | | | | | | | |
| Estonia | | | | | | | | | | | | | | | | | | | |
| Finland | | | | | | | | | | | | | | | | | | | |
| France | | | | | | | | | | | | | | | | | | | |
| Germany | | | | | | | | | | | | | | | | | | | |
| Greece | | | | | | | | | | | | | | | | | | | |
| Hungary | | | | | | | | | | | | | | | | | | | |
| Ireland | | | | | | | | | | | | | | | | | | | |
| Latvia | | | | | | | | | | | | | | | | | | | |
| Lithuania | | | | | | | | | | | | | | | | | | | |
| Luxembourg | | | | | | | | | | | | | | | | | | | |
| Poland | | | | | | | | | | | | | | | | | | | |
| Portugal | | | | | | | | | | | | | | | | | | | |
| The Netherlands | | | | | | | | | | | | | | | | | | | |
| Norway | | | | | | | | | | | | | | | | | | | |
| Slovak Republic | | | | | | | | | | | | | | | | | | | |
| Slovenia | | | | | | | | | | | | | | | | | | | |
| Spain | | | | | | | | | | | | | | | | | | | |
| Sweden | | | | | | | | | | | | | | | | | | | |
| UK | | | | | | | | | | | | | | | | | | | |
| Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp |

Country

Salbutamol

Terbutaline

Fenoterol

Orciprenaline

Reproterol

Carbuterol

Hexoprenaline

Pirbuterol

Clenbuterol

Bitolterol

Procaterol

Beclamethasone

Dexamethasone

Flunisolide

Fluticasone

Budesonide

Triamcinolone

Ipratropium bromide

Oxitropium bromide

Austria

Image 1

Image 2

Image 3

Image 4

Image 5

Image 6

Image 7

Image 8

Image 9

Image 10

Image 11

Belgium

Image 12

Image 13

Image 14

Image 15

Image 16

Image 17

Image 18

Image 19

Image 20

Image 21

Image 22

Cyprus

Image 23

Czech Republic

Image 24

Image 25

Image 26

Image 27

Image 28

Image 29

Image 30

Image 31

Image 32

Image 33

Image 34

Denmark

Image 35

Image 36

Image 37

Image 38

Image 39

Image 40

Image 41

Image 42

Image 43

Image 44

Estonia

Image 45

Image 46

Image 47

Image 48

Image 49

Image 50

Image 51

Image 52

Image 53

Image 54

Image 55

Finland

Image 56

France

Image 57

Germany

Image 58

Image 59

Image 60

Image 61

Image 62

Image 63

Image 64

Image 65

Image 66

Image 67

Image 68

Image 69

Image 70

Image 71

Image 72

Image 73

Image 74

Image 75

Image 76

Greece

Image 77

Image 78

Image 79

Image 80

Image 81

Image 82

Image 83

Image 84

Image 85

Image 86

Image 87

Hungary

Image 88

Image 89

Image 90

Image 91

Image 92

Image 93

Image 94

Image 95

Image 96

Image 97

Image 98

Ireland

Image 99

Latvia

Image 100

Image 101

Image 102

Image 103

Image 104

Image 105

Image 106

Image 107

Image 108

Image 109

Image 110

Lithuania

Image 111

Image 112

Image 113

Image 114

Image 115

Image 116

Image 117

Image 118

Image 119

Image 120

Image 121

Luxembourg

Image 122

Poland

Image 123

Portugal

Image 124

Image 125

Image 126

Image 127

Image 128

Image 129

Image 130

Image 131

Image 132

Image 133

Image 134

The Netherlands

Image 135

Image 136

Image 137

Image 138

Image 139

Image 140

Image 141

Image 142

Image 143

Image 144

Image 145

Norway

Image 146

Image 147

Image 148

Image 149

Image 150

Image 151

Image 152

Image 153

Image 154

Image 155

Image 156

Slovak Republic

Image 157

Image 158

Image 159

Image 160

Image 161

Image 162

Image 163

Image 164

Image 165

Image 166

Image 167

Slovenia

Image 168

Image 169

Image 170

Image 171

Image 172

Image 173

Image 174

Image 175

Image 176

Image 177

Image 178

Spain

Image 179

Sweden

Image 180

UK

Image 181

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp

---

ANNEX II

ESSENTIAL MEDICAL USES

Quota of controlled substances of Group I that may be used in the production of metered dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:

| | 3M Health Care (UK) |
| --- | --- |

3M Health Care (UK)

| | Aventis (UK) |
| --- | --- |

Aventis (UK)

| | Bespak (UK) |
| --- | --- |

Bespak (UK)

| | Boehringer Ingelheim (DE) |
| --- | --- |

Boehringer Ingelheim (DE)

| | Chiesi (IT) |
| --- | --- |

Chiesi (IT)

| | Glaxo Smith Kline (ES, FR, PL, UK) |
| --- | --- |

Glaxo Smith Kline (ES, FR, PL, UK)

| | IG Sprühtechnik (DE) |
| --- | --- |

IG Sprühtechnik (DE)

| | Inyx Pharmaceuticals (UK) |
| --- | --- |

Inyx Pharmaceuticals (UK)

| | IVAX (IE) |
| --- | --- |

IVAX (IE)

| | Laboratorio Aldo-Unión (ES) |
| --- | --- |

Laboratorio Aldo-Unión (ES)

| | Sicor (IT) |
| --- | --- |

Sicor (IT)

| | V.A.R.I. (IT) |
| --- | --- |

V.A.R.I. (IT)

| | Valeas (IT) |
| --- | --- |

Valeas (IT)

| | Valois (FR) |
| --- | --- |

Valois (FR)

---

ANNEX III

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group I and II that may be used for laboratory and analytical uses, are allocated to:

| | Agfa-Gevaert (BE) |
| --- | --- |

Agfa-Gevaert (BE)

| | Bie & Berntsen (DK) |
| --- | --- |

Bie & Berntsen (DK)

| | Biosolve (NL) |
| --- | --- |

Biosolve (NL)

| | Carl Roth (DE) |
| --- | --- |

Carl Roth (DE)

| | Elcom Group (CZ) |
| --- | --- |

Elcom Group (CZ)

| | Honeywell Specialty Chemicals (DE) |
| --- | --- |

Honeywell Specialty Chemicals (DE)

| | Ineos Fluor (UK) |
| --- | --- |

Ineos Fluor (UK)

| | Katholieke Universiteit Leuven (BE) |
| --- | --- |

Katholieke Universiteit Leuven (BE)

| | LGC Promochem (DE) |
| --- | --- |

LGC Promochem (DE)

| | Mallinckrodt Baker (NL) |
| --- | --- |

Mallinckrodt Baker (NL)

| | Merck KGaA (DE) |
| --- | --- |

Merck KGaA (DE)

| | Mikro + Polo (SI) |
| --- | --- |

Mikro + Polo (SI)

| | Panreac Química (ES) |
| --- | --- |

Panreac Química (ES)

| | SDS Solvants (FR) |
| --- | --- |

SDS Solvants (FR)

| | Sanolabor (SI) |
| --- | --- |

Sanolabor (SI)

| | Sigma Aldrich Chemie (DE) |
| --- | --- |

Sigma Aldrich Chemie (DE)

| | Sigma Aldrich Chimie (FR) |
| --- | --- |

Sigma Aldrich Chimie (FR)

| | Sigma Aldrich Company (UK) |
| --- | --- |

Sigma Aldrich Company (UK)

---

ANNEX IV

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group III that may be used for laboratory and analytical uses are allocated to:

| | Ineos Fluor (UK) |
| --- | --- |

Ineos Fluor (UK)

| | Ministry of Defense (NL) |
| --- | --- |

Ministry of Defense (NL)

| | Sigma Aldrich Chimie (FR) |
| --- | --- |

Sigma Aldrich Chimie (FR)

| | Sigma Aldrich Company (UK) |
| --- | --- |

Sigma Aldrich Company (UK)

---

ANNEX V

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group IV that may be used for laboratory and analytical uses, are allocated to:

| | Acros Organics (BE) |
| --- | --- |

Acros Organics (BE)

| | Agfa-Gevaert (BE) |
| --- | --- |

Agfa-Gevaert (BE)

| | Bie & Berntsen (DK) |
| --- | --- |

Bie & Berntsen (DK)

| | Biosolve (NL) |
| --- | --- |

Biosolve (NL)

| | Health Protection Inspectorate-Laboratories (EE) |
| --- | --- |

Health Protection Inspectorate-Laboratories (EE)

| | Institut Scientifique de Service Public (ISSeP) (BE) |
| --- | --- |

Institut Scientifique de Service Public (ISSeP) (BE)

| | Katholieke Universiteit Leuven (BE) |
| --- | --- |

Katholieke Universiteit Leuven (BE)

| | Mallinckrodt Baker (NL) |
| --- | --- |

Mallinckrodt Baker (NL)

| | Merck KGaA (DE) |
| --- | --- |

Merck KGaA (DE)

| | Mikro + Polo (SI) |
| --- | --- |

Mikro + Polo (SI)

| | Panreac Química (ES) |
| --- | --- |

Panreac Química (ES)

| | Rohs Chemie (DE) |
| --- | --- |

Rohs Chemie (DE)

| | SDS Solvants (FR) |
| --- | --- |

SDS Solvants (FR)

| | Sanolabor d.d. (SI) |
| --- | --- |

Sanolabor d.d. (SI)

| | Sigma Aldrich Chemie (DE) |
| --- | --- |

Sigma Aldrich Chemie (DE)

| | Sigma Aldrich Chimie (FR) |
| --- | --- |

Sigma Aldrich Chimie (FR)

| | Sigma Aldrich Company (UK) |
| --- | --- |

Sigma Aldrich Company (UK)

| | Sigma Aldrich Laborchemikalien (DE) |
| --- | --- |

Sigma Aldrich Laborchemikalien (DE)

| | VWR I.S.A.S. (FR) |
| --- | --- |

VWR I.S.A.S. (FR)

| | YA-Kemia Oy (FI) |
| --- | --- |

YA-Kemia Oy (FI)

---

ANNEX VI

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group V that may be used for laboratory and analytical uses are allocated to:

| | Acros Organics (BE) |
| --- | --- |

Acros Organics (BE)

| | Bie & Berntsen (DK) |
| --- | --- |

Bie & Berntsen (DK)

| | Katholieke Universiteit Leuven (BE) |
| --- | --- |

Katholieke Universiteit Leuven (BE)

| | Mallinckrodt Baker (NL) |
| --- | --- |

Mallinckrodt Baker (NL)

| | Merck KGaA (DE) |
| --- | --- |

Merck KGaA (DE)

| | Mikro + Polo (SI) |
| --- | --- |

Mikro + Polo (SI)

| | Panreac Química (ES) |
| --- | --- |

Panreac Química (ES)

| | Sanolabor d.d. (SI) |
| --- | --- |

Sanolabor d.d. (SI)

| | Sigma Aldrich Chemie (DE) |
| --- | --- |

Sigma Aldrich Chemie (DE)

| | Sigma Aldrich Chimie (FR) |
| --- | --- |

Sigma Aldrich Chimie (FR)

| | Sigma Aldrich Company (UK) |
| --- | --- |

Sigma Aldrich Company (UK)

| | VWR I.S.A.S. (FR) |
| --- | --- |

VWR I.S.A.S. (FR)

| | YA-Kemia Oy (FI) |
| --- | --- |

YA-Kemia Oy (FI)

---

ANNEX VII

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group VII that may be used for laboratory and analytical uses are allocated to:

| | Ineos Fluor (UK) |
| --- | --- |

Ineos Fluor (UK)

| | Sigma Aldrich Chimie (FR) |
| --- | --- |

Sigma Aldrich Chimie (FR)

| | Sigma Aldrich Company (UK) |
| --- | --- |

Sigma Aldrich Company (UK)

---

ANNEX VIII

ESSENTIAL LABORATORY USES

Quota of controlled substances of Group IX that may be used for laboratory and analytical uses are allocated to:

| | Ineos Fluor (UK) |
| --- | --- |

Ineos Fluor (UK)

| | Sigma Aldrich Chemie (DE) |
| --- | --- |

Sigma Aldrich Chemie (DE)

---

ANNEX IX

(This Annex is not published because it contains confidential commercial information.)

---